Cargando…

Germline mutations in Japanese familial pancreatic cancer patients

Clinicopathologic and genetic features of familial pancreatic cancer (FPC) in Asian countries remain largely unknown. The main purpose of this study was to determine the prevalence of FPC and to define causative FPC-predisposition genes in a Japanese cohort with pancreatic ductal adenocarcinoma (PDA...

Descripción completa

Detalles Bibliográficos
Autores principales: Takai, Erina, Yachida, Shinichi, Shimizu, Kyoko, Furuse, Junji, Kubo, Emi, Ohmoto, Akihiro, Suzuki, Masami, Hruban, Ralph H., Okusaka, Takuji, Morizane, Chigusa, Furukawa, Toru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342048/
https://www.ncbi.nlm.nih.gov/pubmed/27732944
http://dx.doi.org/10.18632/oncotarget.12490
_version_ 1782513091674636288
author Takai, Erina
Yachida, Shinichi
Shimizu, Kyoko
Furuse, Junji
Kubo, Emi
Ohmoto, Akihiro
Suzuki, Masami
Hruban, Ralph H.
Okusaka, Takuji
Morizane, Chigusa
Furukawa, Toru
author_facet Takai, Erina
Yachida, Shinichi
Shimizu, Kyoko
Furuse, Junji
Kubo, Emi
Ohmoto, Akihiro
Suzuki, Masami
Hruban, Ralph H.
Okusaka, Takuji
Morizane, Chigusa
Furukawa, Toru
author_sort Takai, Erina
collection PubMed
description Clinicopathologic and genetic features of familial pancreatic cancer (FPC) in Asian countries remain largely unknown. The main purpose of this study was to determine the prevalence of FPC and to define causative FPC-predisposition genes in a Japanese cohort with pancreatic ductal adenocarcinoma (PDAC). We reviewed 1,197 patients with a pathologically proven PDAC and found that 88 (7.3%) were FPC patients who had at least one first-degree relative with PDAC. There were no significant differences between the FPC cases and sporadic cases in terms of gender, age, tumor location, stage, family history of any cancer except PDAC, and personal history of smoking, other cancers, diabetes mellitus and chronic pancreatitis. In the FPC patients, we then investigated the prevalence of germline mutations in 21 genes associated with hereditary predispositions for pancreatic, breast and ovarian cancers by means of the next-generation sequencing using a custom multiple-gene panel. We found that eight (14.5%) of the 54 FPC patients with available germline DNA carried deleterious mutations in BRCA2, PALB2, ATM, or MLH1. These results indicate that a significant fraction of patients with PDAC in Japan have a family history of pancreatic cancer, and some of them harbor deleterious causative mutations in known FPC predisposition genes.
format Online
Article
Text
id pubmed-5342048
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-53420482017-03-27 Germline mutations in Japanese familial pancreatic cancer patients Takai, Erina Yachida, Shinichi Shimizu, Kyoko Furuse, Junji Kubo, Emi Ohmoto, Akihiro Suzuki, Masami Hruban, Ralph H. Okusaka, Takuji Morizane, Chigusa Furukawa, Toru Oncotarget Research Paper Clinicopathologic and genetic features of familial pancreatic cancer (FPC) in Asian countries remain largely unknown. The main purpose of this study was to determine the prevalence of FPC and to define causative FPC-predisposition genes in a Japanese cohort with pancreatic ductal adenocarcinoma (PDAC). We reviewed 1,197 patients with a pathologically proven PDAC and found that 88 (7.3%) were FPC patients who had at least one first-degree relative with PDAC. There were no significant differences between the FPC cases and sporadic cases in terms of gender, age, tumor location, stage, family history of any cancer except PDAC, and personal history of smoking, other cancers, diabetes mellitus and chronic pancreatitis. In the FPC patients, we then investigated the prevalence of germline mutations in 21 genes associated with hereditary predispositions for pancreatic, breast and ovarian cancers by means of the next-generation sequencing using a custom multiple-gene panel. We found that eight (14.5%) of the 54 FPC patients with available germline DNA carried deleterious mutations in BRCA2, PALB2, ATM, or MLH1. These results indicate that a significant fraction of patients with PDAC in Japan have a family history of pancreatic cancer, and some of them harbor deleterious causative mutations in known FPC predisposition genes. Impact Journals LLC 2016-10-06 /pmc/articles/PMC5342048/ /pubmed/27732944 http://dx.doi.org/10.18632/oncotarget.12490 Text en Copyright: © 2016 Takai et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Takai, Erina
Yachida, Shinichi
Shimizu, Kyoko
Furuse, Junji
Kubo, Emi
Ohmoto, Akihiro
Suzuki, Masami
Hruban, Ralph H.
Okusaka, Takuji
Morizane, Chigusa
Furukawa, Toru
Germline mutations in Japanese familial pancreatic cancer patients
title Germline mutations in Japanese familial pancreatic cancer patients
title_full Germline mutations in Japanese familial pancreatic cancer patients
title_fullStr Germline mutations in Japanese familial pancreatic cancer patients
title_full_unstemmed Germline mutations in Japanese familial pancreatic cancer patients
title_short Germline mutations in Japanese familial pancreatic cancer patients
title_sort germline mutations in japanese familial pancreatic cancer patients
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342048/
https://www.ncbi.nlm.nih.gov/pubmed/27732944
http://dx.doi.org/10.18632/oncotarget.12490
work_keys_str_mv AT takaierina germlinemutationsinjapanesefamilialpancreaticcancerpatients
AT yachidashinichi germlinemutationsinjapanesefamilialpancreaticcancerpatients
AT shimizukyoko germlinemutationsinjapanesefamilialpancreaticcancerpatients
AT furusejunji germlinemutationsinjapanesefamilialpancreaticcancerpatients
AT kuboemi germlinemutationsinjapanesefamilialpancreaticcancerpatients
AT ohmotoakihiro germlinemutationsinjapanesefamilialpancreaticcancerpatients
AT suzukimasami germlinemutationsinjapanesefamilialpancreaticcancerpatients
AT hrubanralphh germlinemutationsinjapanesefamilialpancreaticcancerpatients
AT okusakatakuji germlinemutationsinjapanesefamilialpancreaticcancerpatients
AT morizanechigusa germlinemutationsinjapanesefamilialpancreaticcancerpatients
AT furukawatoru germlinemutationsinjapanesefamilialpancreaticcancerpatients